332 related articles for article (PubMed ID: 2150552)
1. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
[TBL] [Abstract][Full Text] [Related]
2. [Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F].
du Bois A; Meerpohl HG; Wilhelm C; Quaas L; Barnickel I; Pfleiderer A
Onkologie; 1990 Oct; 13(5):364-8. PubMed ID: 2150551
[TBL] [Abstract][Full Text] [Related]
3. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
[TBL] [Abstract][Full Text] [Related]
7. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
[TBL] [Abstract][Full Text] [Related]
8. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
10. [Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
Marschner NW; Adler M; Jaenicke F; Albrecht U; Nagel GA
Onkologie; 1990 Aug; 13(4):313-5. PubMed ID: 2146577
[TBL] [Abstract][Full Text] [Related]
11. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
Schmoll HJ
Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897
[TBL] [Abstract][Full Text] [Related]
12. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
13. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
Hesketh PJ; Murphy WK; Lester EP; Gandara DR; Khojasteh A; Tapazoglou E; Sartiano GP; White DR; Werner K; Chubb JM
J Clin Oncol; 1989 Jun; 7(6):700-5. PubMed ID: 2523957
[TBL] [Abstract][Full Text] [Related]
14. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
16. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Egan AP; Taggart JR; Bender CM
Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
[TBL] [Abstract][Full Text] [Related]
17. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Depierre A
Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
[TBL] [Abstract][Full Text] [Related]
19. Ondansetron. Therapeutic use as an antiemetic.
Milne RJ; Heel RC
Drugs; 1991 Apr; 41(4):574-95. PubMed ID: 1711961
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
Safonova SA; Gershanovich ML; Punanov IuA; Kolygin BA
Vopr Onkol; 1999; 45(4):424-8. PubMed ID: 10532104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]